Aadi Bioscience reports FY2022 revenue $15.2M; PRECISION-1 data Q2 2023

Whitehawk Therapeutics, Inc.

FY 2022 total revenue $15.2M from FYARRO (10 months); Q4 net product sales $5.2M (+23% QoQ).
Net loss $60.5M for FY2022 vs $110.1M in FY2021 (prior year incl $74.2M impairment).
Cash $172.6M at Dec 31, 2022; cash runway into 2025 after $72.5M Q4 financing.
PRECISION-1 trial preliminary data on TSC1/TSC2 alterations expected Q2 2023.
Appointed Dr. Mohammad Hirmand to Board; collaboration with Mirati on adagrasib combo trial start Q2 2023.

item 2.02 item 9.01 item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Mohammad Hirmand

Class II Director

WHWK · Whitehawk Therapeutics, Inc.

Effective: 2023-03-27
Filed: March 28, 2023, 7:59 PM ET

On March 24, 2023, Mohammad Hirmand, M.D. was appointed a Class II director by the Board of Directors (the “ Board ”) of the Company, effective March 27, 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Whitehawk Therapeutics, Inc. reported Fiscal year ended December 31, 2022 results: revenue $15.2 million, net income $60.5 million net loss.

Period: Fiscal year ended December 31, 2022
Revenue: $15.2 million
Net income: $60.5 million net loss
Result: reported results

Exact text from the filing

Total revenue for the quarter ended December 31, 2022 was $5.2 million, and $15.2 million for the full-year ended December 31, 2022, resulting from sales of FYARRO. • Net loss for the three months ended December 31, 2022 was $13.9 million as compared to $16.0 million for the three months ended December 31, 2021. Net loss for the full-year 2022 ended December 31, 2022 was $60.5 million, as compared to $110.1 million for the period in 2021 (The prior year included the non-cash impairment charge of $74.2 million related to the acquired contract intangible asset incurred in conjunction with the Aerpio merger).

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Whitehawk Therapeutics, Inc. reported Three months ended December 31, 2022 results: revenue $5.2 million, net income $13.9 million net loss.

Period: Three months ended December 31, 2022
Revenue: $5.2 million
Net income: $13.9 million net loss
Result: reported results

Exact text from the filing

Total revenue for the quarter ended December 31, 2022 was $5.2 million, and $15.2 million for the full-year ended December 31, 2022, resulting from sales of FYARRO. • Net loss for the three months ended December 31, 2022 was $13.9 million as compared to $16.0 million for the three months ended December 31, 2021.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Mohammad Hirmand was appointed as Class II Director at Whitehawk Therapeutics, Inc..

Action: appointed
Role: Class II Director

Exact text from the filing

On March 24, 2023, Mohammad Hirmand, M.D. was appointed a Class II director by the Board of Directors (the “ Board ”) of the Company, effective March 27, 2023.

View on SEC.gov

23 earnings releases filed in the last 30 days. Browse all earnings releases →

Whitehawk Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-009345

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.